171 related articles for article (PubMed ID: 37226709)
1. Subgroup-specific gene expression profiles and mixed epistasis in chronic lymphocytic leukemia.
Lütge A; Lu J; Hüllein J; Walther T; Sellner L; Wu B; Rosenquist R; Oakes CC; Dietrich S; Huber W; Zenz T
Haematologica; 2023 Oct; 108(10):2664-2676. PubMed ID: 37226709
[TBL] [Abstract][Full Text] [Related]
2. The protein landscape of chronic lymphocytic leukemia.
Meier-Abt F; Lu J; Cannizzaro E; Pohly MF; Kummer S; Pfammatter S; Kunz L; Collins BC; Nadeu F; Lee KS; Xue P; Gwerder M; Roiss M; Hüllein J; Scheinost S; Dietrich S; Campo E; Huber W; Aebersold R; Zenz T
Blood; 2021 Dec; 138(24):2514-2525. PubMed ID: 34189564
[TBL] [Abstract][Full Text] [Related]
3. Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.
Rodríguez-Vicente AE; Díaz MG; Hernández-Rivas JM
Cancer Genet; 2013 Mar; 206(3):49-62. PubMed ID: 23531595
[TBL] [Abstract][Full Text] [Related]
4. Clonal evolution in chronic lymphocytic leukemia: analysis of correlations with IGHV mutational status, NOTCH1 mutations and clinical significance.
López C; Delgado J; Costa D; Villamor N; Navarro A; Cazorla M; Gómez C; Arias A; Muñoz C; Cabezas S; Baumann T; Rozman M; Aymerich M; Colomer D; Pereira A; Cobo F; López-Guillermo A; Campo E; Carrió A
Genes Chromosomes Cancer; 2013 Oct; 52(10):920-7. PubMed ID: 23893575
[TBL] [Abstract][Full Text] [Related]
5. Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group.
Roos-Weil D; Nguyen-Khac F; Chevret S; Touzeau C; Roux C; Lejeune J; Cosson A; Mathis S; Feugier P; Leprêtre S; Béné MC; Baron M; Raynaud S; Struski S; Eclache V; Sutton L; Lesty C; Merle-Béral H; Cymbalista F; Ysebaert L; Davi F; Leblond V;
Genes Chromosomes Cancer; 2018 Nov; 57(11):533-540. PubMed ID: 30203893
[TBL] [Abstract][Full Text] [Related]
6. Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
Baliakas P; Hadzidimitriou A; Sutton LA; Rossi D; Minga E; Villamor N; Larrayoz M; Kminkova J; Agathangelidis A; Davis Z; Tausch E; Stalika E; Kantorova B; Mansouri L; Scarfò L; Cortese D; Navrkalova V; Rose-Zerilli MJ; Smedby KE; Juliusson G; Anagnostopoulos A; Makris AM; Navarro A; Delgado J; Oscier D; Belessi C; Stilgenbauer S; Ghia P; Pospisilova S; Gaidano G; Campo E; Strefford JC; Stamatopoulos K; Rosenquist R;
Leukemia; 2015 Feb; 29(2):329-36. PubMed ID: 24943832
[TBL] [Abstract][Full Text] [Related]
7. Distinct immunoglobulin heavy chain variable region gene repertoire and lower frequency of del(11q) in Taiwanese patients with chronic lymphocytic leukaemia.
Huang YJ; Kuo MC; Chang H; Wang PN; Wu JH; Huang YM; Ma MC; Tang TC; Kuo CY; Shih LY
Br J Haematol; 2019 Oct; 187(1):82-92. PubMed ID: 31230372
[TBL] [Abstract][Full Text] [Related]
8. IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics.
Nadeu F; Royo R; Clot G; Duran-Ferrer M; Navarro A; Martín S; Lu J; Zenz T; Baumann T; Jares P; Puente XS; Martín-Subero JI; Delgado J; Campo E
Blood; 2021 May; 137(21):2935-2946. PubMed ID: 33211804
[TBL] [Abstract][Full Text] [Related]
9. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
Sandoval-Sus JD; Chavez JC; Dalia S; Naqvi SMH; Talati C; Nodzon L; Kharfan-Dabaja MA; Pinilla-Ibarz J
Leuk Lymphoma; 2018 Jan; 59(1):59-68. PubMed ID: 28641468
[TBL] [Abstract][Full Text] [Related]
10. A new genetic abnormality leading to TP53 gene deletion in chronic lymphocytic leukaemia.
López C; Baumann T; Costa D; López-Guerra M; Navarro A; Gómez C; Arias A; Muñoz C; Rozman M; Villamor N; Colomer D; Montserrat E; Campo E; Carrió A
Br J Haematol; 2012 Mar; 156(5):612-8. PubMed ID: 22150335
[TBL] [Abstract][Full Text] [Related]
11. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
12. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
[TBL] [Abstract][Full Text] [Related]
13. SF3B1 and IGHV gene mutation status predict poor prognosis in Japanese CLL patients.
Mitsui T; Koiso H; Nakahashi H; Saitoh A; Shimizu H; Ishizaki T; Ogawa Y; Takizawa M; Yokohama A; Saitoh T; Jinbo T; Ogura H; Handa H; Sawamura M; Sakura T; Karasawa M; Murakami H; Nojima Y; Tsukamoto N
Int J Hematol; 2016 Feb; 103(2):219-26. PubMed ID: 26588928
[TBL] [Abstract][Full Text] [Related]
14. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
[TBL] [Abstract][Full Text] [Related]
16. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.
Shi K; Sun Q; Qiao C; Zhu H; Wang L; Wu J; Wang L; Fu J; Young KH; Fan L; Xia Y; Xu W; Li J
Cancer Med; 2020 Feb; 9(3):999-1007. PubMed ID: 31849198
[TBL] [Abstract][Full Text] [Related]
17. Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations.
López C; Delgado J; Costa D; Conde L; Ghita G; Villamor N; Navarro A; Cazorla M; Gómez C; Arias A; Muñoz C; Baumann T; Rozman M; Aymerich M; Colomer D; Cobo F; Campo E; López-Guillermo A; Montserrat E; Carrió A
Genes Chromosomes Cancer; 2012 Sep; 51(9):881-9. PubMed ID: 22619094
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
[TBL] [Abstract][Full Text] [Related]
19. [Some genomic aberrations in B-cell chronic lymphocytic leukemia and their clinical relevance. Part II. Trisomy 12 in B-cell chronic lymphocytic leukemia detected by fluorescence in situ hybridization].
Wasik-Szczepanek E; Rupniewska ZM; Koczkodaj D; Bojarska A
Pol Arch Med Wewn; 2003 Dec; 110(6):1431-8. PubMed ID: 15052938
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL.
Kern W; Bacher U; Haferlach C; Dicker F; Alpermann T; Schnittger S; Haferlach T
Br J Haematol; 2012 Apr; 157(1):86-96. PubMed ID: 22224978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
